Cardiac MRI for Tricuspid Regurgitation

Recruiting in Palo Alto (17 mi)

Overseen byMohamad Alkhouli, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this research is to assess the severity of tricuspid regurgitation (a disorder in which the tricuspid valve in the heart does not close tight enough) using cardiac magnetic resonance imaging (MRI).

Eligibility Criteria

This trial is for individuals with moderate or severe tricuspid regurgitation, which is when the heart's tricuspid valve doesn't close properly. Participants must not have a pacemaker/defibrillator that interferes with MRI, any prior tricuspid valve replacements, planned surgery on the tricuspid valve, or primary liver disease.

Inclusion Criteria

You have moderate or severe tricuspid regurgitation.

Exclusion Criteria

You have had a replacement of your tricuspid valve in the past.

You have a pacemaker or defibrillator that would make it difficult to take MRI pictures.

You are scheduled to have surgery on your tricuspid valve.

See 1 more

Treatment Details

Interventions

Cardiac Magnetic Resonance (Procedure)

Trial OverviewThe study aims to evaluate how well cardiac magnetic resonance imaging (MRI) can determine the severity of tricuspid regurgitation in patients' hearts.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Moderate or severe tricuspid regurgitationExperimental Treatment1 Intervention

40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.